Rockefeller Capital Management L.P. Blueprint Medicines Corp Transaction History

Rockefeller Capital Management L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	SELL	$49.93 - $77.7 $1,298 - $2,020	-26 Reduced 48.15%	28 $1,000
Q2 2022 Aug 12, 2022	SELL	$45.23 - $70.15 $542 - $841	-12 Reduced 18.18%	54 $2,000
Q1 2022 May 13, 2022	SELL	$54.1 - $110.08 $9,251 - $18,823	-171 Reduced 72.15%	66 $4,000
Q4 2021 Feb 14, 2022	SELL	$94.25 - $115.99 $25,070 - $30,853	-266 Reduced 52.88%	237 $25,000
Q3 2021 Nov 12, 2021	BUY	$80.98 - $109.47 $39,518 - $53,421	488 Added 3253.33%	503 $51,000
Q2 2021 Aug 10, 2021	BUY	$82.78 - $101.0 $1,241 - $1,515	15 New	15 $1,000
Q4 2019 Feb 07, 2020	SELL	$66.73 - $82.59 $52,449 - $64,915	-786 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$72.9 - $101.41 $874 - $1,216	-12 Reduced 1.5%	786 $58,000
Q2 2019 Aug 09, 2019	BUY	$73.54 - $97.8 $57,434 - $76,381	781 Added 4594.12%	798 $75,000
Q1 2019 May 10, 2019	BUY	$48.7 - $86.6 $827 - $1,472	17 New	17 $1,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.